State of the art of palliative therapy

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 4, 2011, Pages 411-419

  Seregni, E ^a   Padovano, B ^a   Coliva, A ^a   Zecca, E ^a   Bombardieri, E ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Neoplasm metastasis; Pain; Radiopharmaceuticals

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CODEINE; ETIDRONIC ACID RE 186; FENTANYL; LEXIDRONAM SAMARIUM SM 153; METHADONE; MORPHINE; OPIATE; OXYCODONE; OXYMORPHONE; PAMIDRONIC ACID; PARACETAMOL; PHOSPHORUS 32; RADIOPHARMACEUTICAL AGENT; STRONTIUM 89; ZOLEDRONIC ACID;

AGITATION; ANALGESIA; BONE NECROSIS; BONE PAIN; CONFUSION; CONJUNCTIVITIS; CONSTIPATION; EXTERNAL BEAM RADIOTHERAPY; FLU LIKE SYNDROME; HALLUCINATION; HUMAN; HYPERPLASIA; MEDICAL LITERATURE; PALLIATIVE THERAPY; PARADOXICAL HYPERPLASIA; PATIENT SELECTION; REVIEW; SCLERITIS; SIDE EFFECT; SOMNOLENCE; SYSTEMIC THERAPY; THERAPY EFFECT; TOXICITY; TREATMENT INDICATION; UVEITIS;

ANALGESICS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; PAIN; PALLIATIVE CARE; PATIENT SELECTION; RADIOPHARMACEUTICALS;

EID: 80755169731     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Lam MG, de Klerk JM, van Rijk PP, Zonnenberg BA. Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. Anticancer Agents Med Chem 2007;7:381-97. (Pubitemid 47099046)
2. Clines GA, Giuse TA. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008;10:e7.
3. Hillegonds DJ, Franklin S, Shelton DK, Vijayakumar S, Vijayakumar V. The management of painful bone metastases with an emphasis on radionuclide therapy. J Natl Med Assoc 2007;99:785-94. (Pubitemid 47076147)
4. Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001;42:895-906. (Pubitemid 32537437)
5. Chrsito PJ, Mazloom-Doost D. Cancer pain and analgesia. Ann N Y Acad Sci 2008;1138:278-98.
6. McNicol E, Strassels S, Goudas L, Lau J, Carr D. Non-steroidal anti-inflammatory drugs, alone or combined with opioids for cancer pain: a systematic review. J Clin Oncol 2004;22:1975-92. (Pubitemid 41095191)
7. Paes FM, Serafini AN. Systemic Metabolic Radiopharmaceutical therapy in the treatment fo metastatic bone pain. Semin Nucl Med 2010;40:89-104.
8. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W et al. Zolendronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-200.
9. Wong R, Shukla VK, Mensinkai S, Wiffen P. Bisphosphonate agents for the management of pain secondary to bone metastases: a systematic review of effectiveness and safety. Technology Report no. 45. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), Jan 2004.
10. Zhang L, Guan Z, He Y. Randomized comparative clinic trial of treatment of bone metastatic disease by infusion of Pamidronate and cloridrate. Chin J Cancer 1997;16:340-432.
11. Diel IJ, Marschner N, Kindler M, Lange O, Untch M, Hurtz HJ et al. Continuai oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases, (abstract 488). Proceedings of Annual Meeting of American Society of Clinical Oncologists, 1999.
12. Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidraonte and oral clodronate on symptoms and bone resorption in patients with metastatc bone disease. Ann Oncol 2001;12:1433-8. (Pubitemid 33100250)
13. Lin A, Ray ME. Targeted and systemic radiotherapy in the treatment of bone metastases. Cancer Metastasis Rev 2006;25:669-75. (Pubitemid 46071871)
14. Tong D, Gillick L, Handrickson FR. The palliation of symptomatic osseous metastases: final results of the study by the Radiation Theraphy Oncology Group. Cancer 1982;50:893-9. (Pubitemid 12047122)
15. Poulter CA, Cosmatos D, Rubin P, Urtasun R, Cooper JS, Kuske RR et al. A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases. Int J Radiat Oncol Biol Phys 1992;23:207-14.
16. Dy SM, Asch SM, Naeim A et al. Evidence-based standards for cancer pain management. J Clin Oncol 2008,26:3879-3885
17. Auclerc G, Antoine EC, Cajfinger F, Brunet-Pommeyrol A, Agazia C, Khayat D. Management of advanced prostate cancer. Oncologist 2000;5:36-44. (Pubitemid 30127543)
18. Farquhar-Smith P. Anaesthetic/interventional techniques. In: Davies A, editor. Cancer-related bone pain. Oxford: Oxford University Press: 2007. p. 85-97.
19. Gangi A, Dietemann JL, Schultz A, Mortazavi R, Jeung MY, Roy C. Interventional radiology procedures with CT guidance in cancer pain management. Radiographics 1996;16:1289-304. (Pubitemid 126448182)
20. Gangi A, Guth S, Imbert JP, Marin H, Dietemann JL. Percutaneous vertebroplasty:indications, technique and results. Radiographics 2003;23:e10.
21. Legroux-Gérot I, Lormeau C, Boutry N, Cotten A, Duquesnoy B, Cortet B. Long-term follow-up of vertebral osteoporotic fractures treated by percutaneous vertebroplasty. Clinical Reumatology 2004;23:310-7. (Pubitemid 39193786)
22. Cortet B, Cotten A, Boutry N, Dewatre F, Flipo RM, Duquesnoy B et al. Percutaneous vertebroplasty in patients with osteolytic metastases or multiple myeloma. Revue du Rhumatisme 1997;64:117-83.
23. Cotten A, Dewatre F, Cortet B, Assaker R, Leblond D, Duquesnoy B et al. Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and leakage of methyl methacrylate at clinical follow up. Radiology 1996;200:525-30. (Pubitemid 26249909)
24. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer. A systematic review. Lancet Oncol 2005;6:392-400. (Pubitemid 40753745)
25. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004;45:1358-65. (Pubitemid 47618536)
26. Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 2008;35:1934-40.
27. Lewington VJ. Cancer therapy using bone-seeking isotopes. Phys Med Biol 1996;41:2027-42. (Pubitemid 26333638)
28. Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 2006;39:35-41. (Pubitemid 43842022)
29. 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 2008:35:756-65.
30. Marcus CS, Saeed S, Mlikotic A, Mishkin F, Pham HL, Javellana T et al. Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP. Clin Nucl Med 2002;27:427-30. (Pubitemid 34546817)
31. Menda Y, Bushnell DL, Williams RD, Miller S, Thomas MO. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Clin Nucl Med 2000;25:698-700. (Pubitemid 30664434)
32. Taylor AJ Jr. Strontium-89 for the palliation of bone pain due to metastatic disease. J Nucl Med 1994;35:2054.
33. Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJ, Ackery DM. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med 1988;29:549-57.
34. Pons F, Herranz R, Garcia A, Vidal-Sicart S, Conill C, Grau JJ et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 1997;24:1210-4. (Pubitemid 27477612)
35. Baziotis N, Yakoumakis E, Zissimopoulos A, Geronicola-Trapali X, Malamitsi J, Proukakis C. Strontium-89 chloride in the treatment of bone metastases from breast cancer. Oncology 1998;55:377-81. (Pubitemid 28396046)
36. Lee CK, Aeppli DM, Unger J, Boudreau RJ, Levitt SH. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience. Am J Clin Oncol 1996;19:102-7.
37. Mertens WC, Stitt L, Porter AT. Strontium-89 therapy and 7elief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship? Am J Clin Oncol 1993;16:238-42. (Pubitemid 23184387)
38. Nilsson S, Strang P, Ginman C, Zimmermann R, Edgren M, Nordström B et al. Palliation of bone pain in prostate cancer using chemoteraphy and strontium-89. A randomized phase II study. J Pain Symptom Manage 2005;29:352-7. (Pubitemid 40602515)
39. Windsor PM. Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-years experience. Clin Oncol 2001;13:219-27. (Pubitemid 32600215)
40. Kraeber-Bodéré F, Campion L, Rousseau C, Bourdin S, Chatal JF, Resche I. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 2000;27:1487-93.
41. Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A. A multicentre observational study of radionuclide theraphy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001;28:788-98. (Pubitemid 32662540)
42. Kavakli K, Aydogdu S, Taner M, Duman Y, Balkan C, Karapinar DY et al. Radioisotope synovectomy with rhenium 186 in haemophilic synovitis for elbows, ankles and shoulders. Haemophilia 2008;14:518-23. (Pubitemid 351638739)
43. 186Re-HEDP) for the treatment of hemophilic arthropathy: first results. Clin J Pain 2007;23:612-8.
44. De Klerk JM, Zonnenberg BA, Blijham GH, Van Het Schip AD, Hoekstra A, Han SH et al. Treatment of metastatc bone pain using the bone seeking radiopharmaceutical Re-186-HEDP. Anti-cancer Res 1997;17:1773-7. (Pubitemid 27263160)
45. de Klerk JM, Zonnenberg BA, van het Schip AD, van Dijk A, Han SH, Quirijnen JM et al. Dose escalation study of rhenium 186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med 1994;21:1114-20. (Pubitemid 24304438)
46. de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Quirijnen JM, Blijham GH et al. Phase I study of rhenium 186 HEDP in patients with bone metastases originating from breast cancer. J Nucl Med 1996;37:244-9. (Pubitemid 26150896)
47. Maxon HR 3rd, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R et al. Rhenium 186(Sn)HEDP for treatment of painful osseous metastases: results of double-blind crossover camparision with placebo. J Nucl Med 1991;32:1877-81.
48. Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S et al. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 2001;66:101-9. (Pubitemid 32521416)
49. Sciuto R, Tofani A, Festa A, Giannarelli D, Pasqualoni R, Maini CL. Short and long term effects of 186Re-1.1-hydroxythylidene diphosphonate in treatment of painful bone metastases. J Nucl Med 2000;41:647-654 (Pubitemid 30207741)
50. Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A. Samarium-153-EDTMP: pharmacokinetics, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992;33:1451-8.
51. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993;34:1839-44. (Pubitemid 23331244)
52. Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M et al. Samarium-153-EDTMP biodistribution and dosimetry examination. J Nucl Med 1993:34:1031-6.
53. Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 2007;28:623-30. (Pubitemid 47067049)
54. Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS et al. Multicentre trail on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 1999;26:2-7.
55. Sapienza MT, Ono CR, Guimarães MI, Watanabe T, Costa PA, Buchpiguel CA. Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy. Rev Hosp Clin Fac Med Sao Paulo 2004;59:321-8.
56. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE et al. Samarium-153- lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004,63:940-5. (Pubitemid 38596683)
57. Serafini AN. Samarium Sm -153-lexidronam for the palliation of bone pain associated with metastases. Cancer 2000;88(Suppl 12):2934-9. (Pubitemid 30413176)
58. Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R et al. A dose-controlled study of 153-Sm-ethylenediamidetetrame-thylenphosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33:1583-91. (Pubitemid 28123479)
59. Sartor O, Reid RH, Bushnell DL, Quick DP, EU PJ. Safety and efficacy of repeat administration of samarium Sm 153 lexidronam to patients with metastatic bone pain. Cancer 2007;109:637-43. (Pubitemid 46190974)
60. Lam MG, de Klerk JM, Zonnenbereg BA. Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and Samarium-153-ethylenediaminetetramethylphosphonic acid combined. J Palliat Med 2009;12:649-51.
61. Máthé D, Balogh L, Polyák A, Király R, Márián T, Pawlak D et al. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent. Nucl Med Biol 2010;37:215-26.
62. Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009;27:2429-35.
63. Dispenzieri A, Wiseman GA, Lacy MQ, Hayman SR, Kumar SK, Buadi F et al. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Am J Hematol 2010,85:409-13.